

What is claimed is:

1. Polymorph forms 1 and 2 of descarbonylethoxyloratadine hemifumarate having by the following x-ray powder diffraction pattern expressed in terms of "d" spacing and relative intensities ("I/I<sub>0</sub>"):
 

<u>POLYMORPH 1</u>		<u>POLYMORPH 2</u>	
<u>d</u>	<u>I/I<sub>0</sub></u>	<u>d</u>	<u>I/I<sub>0</sub></u>
12.32	26	14.14	14
10.53	11	10.74	13
8.444	19	7.158	39
8.149	16	7.084	20
6.550	25	5.983	12
6.281	22	5.663	61
6.185	35	5.365	33
6.084	19	5.267	100
5.553	88	5.064	12
5.373	64	4.973	46
5.096	59	4.809	16
4.960	41	4.745	43
4.745	34	4.477	32
4.470	26	4.449	26
4.403	30	4.399	60
4.365	46	4.317	54
4.159	84	4.012	49
4.124	73	3.772	26
4.061	35	3.745	61
3.750	79	3.722	97
3.716	100	3.590	88
3.659	27	3.561	59
3.589	14	3.385	24
3.398	11	2.986	17
3.362	16	2.949	11
3.277	10	2.836	20
3.090	23	2.778	10
3.051	11	2.616	10
3.003	15	2.481	12
2.784	10		
2.507	12		

2. A pharmaceutical composition comprising an anti-allergic effective amount of the polymorph forms of descarbonylethoxyloratadine hemifumarate of claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising an anti-allergic effective amount of the polymorph form 1 descarbonylethoxyloratadine hemifumarate of claim 2 and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising an anti-allergic effective amount of the polymorph form 2 descarbonylethoxyloratadine hemifumarate of claim 2 and a pharmaceutically acceptable carrier.
5. A method of treating allergic reactions in a mammal which comprises administering to said mammal an anti-allergic effective amount of the either of the polymorph forms of descarbonylethoxyloratadine hemifumarate of claim 1.
6. The process of preparing the polymorph forms of descarbonylethoxyloratadine hemifumarate comprising:
  - a) mixing the ethanolic solution of desloratadine and fumaric acid at a temperature of from about 55°C to 70°C, and stirring for 30 to 45 minutes after mixing, and thereafter filtering the solid thereby prepared in hot condition; to yield the polymorphic form 2 having a DSC of 232°C ± 2°C; or
  - b) mixing the ethanolic solution of desloratadine and fumaric acid at a temperature of from about 15°C to room temperature (25°C) and stirring at this temperature for 30 to 45 minutes, then filtering at room temperature; to yield the polymorphic form 1 having a DSC of 224°C ± 2°C.